What is HC Wainwright’s Forecast for RCUS Q1 Earnings?

Arcus Biosciences, Inc. (NYSE:RCUS) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Arcus Biosciences in a research report issued on Tuesday, February 18th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($1.30) per share for the quarter. HC Wainwright has a “Neutral” rating and a $18.00 price objective on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.15) EPS and FY2029 earnings at ($1.80) EPS.

RCUS has been the topic of a number of other research reports. Barclays boosted their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research report on Thursday, November 7th. Morgan Stanley dropped their target price on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday. Finally, Bank of America reduced their price target on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Arcus Biosciences has an average rating of “Moderate Buy” and an average target price of $29.50.

Arcus Biosciences Price Performance

RCUS stock opened at $10.76 on Thursday. The stock has a market cap of $984.21 million, a price-to-earnings ratio of -3.41 and a beta of 0.84. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The company has a 50 day simple moving average of $14.02 and a 200 day simple moving average of $15.56. Arcus Biosciences has a 1 year low of $10.63 and a 1 year high of $20.31.

Hedge Funds Weigh In On Arcus Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of RCUS. Woodline Partners LP grew its holdings in Arcus Biosciences by 1.3% during the 4th quarter. Woodline Partners LP now owns 3,523,937 shares of the company’s stock worth $52,471,000 after acquiring an additional 45,497 shares during the period. Two Sigma Advisers LP boosted its position in shares of Arcus Biosciences by 35.8% during the 4th quarter. Two Sigma Advisers LP now owns 58,800 shares of the company’s stock valued at $876,000 after purchasing an additional 15,500 shares in the last quarter. Two Sigma Investments LP grew its stake in Arcus Biosciences by 8.1% during the fourth quarter. Two Sigma Investments LP now owns 146,686 shares of the company’s stock worth $2,184,000 after purchasing an additional 11,027 shares during the period. Tema Etfs LLC bought a new stake in Arcus Biosciences in the fourth quarter worth approximately $331,000. Finally, ProShare Advisors LLC lifted its stake in Arcus Biosciences by 44.4% in the fourth quarter. ProShare Advisors LLC now owns 16,379 shares of the company’s stock valued at $244,000 after buying an additional 5,038 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Activity

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the sale, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. This represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 12.30% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.